Experimental Hematology
Volume 38, Issue 11 , Pages 1058-1065 , November 2010

Oxidative stress is increased in primary and post−polycythemia vera myelofibrosis

  • Claudia Vener

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • Corresponding Author InformationOffprint requests to: Claudia Vener, M.D., Ph.D., U.O. Ematologia, Centro Trapianti di Midollo, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, Milano 20122, Italy
    • Drs. Vener and Novembrino contributed equally to this work.
    • ,
  • Cristina Novembrino

      Affiliations

    • Dipartimento di Scienze Neurologiche Centro “Dino Ferrari”, Milan, Italy
    • University of Milan, Milan, Italy
    • Drs. Vener and Novembrino contributed equally to this work.
    • ,
  • Fabrizia Bamonti Catena

      Affiliations

    • University of Milan, Milan, Italy
    • Cattedra di Biochimica Clinica, Dipartimento di Scienze Mediche, Milan, Italy
    • ,
  • Nicola Stefano Fracchiolla

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • ,
  • Umberto Gianelli

      Affiliations

    • University of Milan, Milan, Italy
    • U.O.C. di Anatomia Patologica, Milan, Italy
    • ,
  • Federica Savi

      Affiliations

    • University of Milan, Milan, Italy
    • U.O.C. di Anatomia Patologica, Milan, Italy
    • ,
  • Franca Radaelli

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • ,
  • Elisa Fermo

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • ,
  • Agostino Cortelezzi

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • University of Milan, Milan, Italy
    • ,
  • Silvia Lonati

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • University of Milan, Milan, Italy
    • ,
  • Marzia Menegatti

      Affiliations

    • University of Milan, Milan, Italy
    • A. Bianchi Bonomi Centro Trombosi ed Emofilia, Dipartimento di Medicina Interna e Fondazione Luigi Villa, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
    • ,
  • Giorgio Lambertenghi Deliliers

      Affiliations

    • Dipartimento di Scienze Mediche, Ematologia, Centro Trapianti di Midollo, Milan, Italy
    • University of Milan, Milan, Italy

Received 4 October 2009 ,Revised 6 July 2010 ,Accepted 9 July 2010.

References 

  1. Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer. 2005;103:32–43
  2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265
  3. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954–2970
  4. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981–1983
  5. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 positive cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249–3255
  6. Tefferi A. New insights into the pathogenesis and drug treatment of myelofibrosis. Curr Opin Hematol. 2006;13:87–92
  7. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684–690
  8. Cervantes F, Pereira A, Esteve J, et al. Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635–640
  9. Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Baillieres Clin Haematol. 1998;11:751–767
  10. Mesa RA, Tefferi A. Survival and outcomes to therapy in leukemic transformation of myelofibrosis with myeloid metaplasia: a single institution experience with 91 patients. [Abstract] Blood. 2003;102:917–918a
  11. Barosi G, Bacigalupo A. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Curr Opin Hematol. 2006;13:74–78
  12. Faurscou M, Nielsen OJ, Jensen MK, Hasselbalch HC. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Am J Hematol. 2000;65:136–140
  13. Nexo E, Hvas AM, Bleie Ø, et al. Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. Clin Chem. 2002;48:1768–1771
  14. Nexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holo-transcobalamin, a marker of vitamin B12 deficiency. Clin Chem. 2002;48:561–562
  15. Refsum H, Johnston C, Guttormsen AB, Nexo E. Holotranscobalamin and total transcobalamin in human plasma: determination, determinants and reference values in healthy adults. Clin Chem. 2006;52:129–137
  16. Bounous G, Molson JN. The antioxidant system. Anticancer Res. 2003;23:1411–1415
  17. Sachdev S, Davies KJ. Production, detection, and adaptive responses to free radicals in exercise. Free Radic Biol Med. 2008;44:215–223
  18. Halliwell B, Gutteridge JMC. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet. 1984;1:129–137
  19. Stadtman ER. Role of oxidant species in aging. Curr Med Chem. 2004;11:1105–1112
  20. Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol. 2008;28:254–264
  21. Zou CG, Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal. 2005;7:547–559
  22. Thiele J, Kvasnicka HM, Tefferi A, Barosi G, Orazi A, Vardiman JW. Primary myelofibrosis. In:  Swerdlow SH,  Campo E,  Harris NL editor. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008;p. 44–47
  23. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–1132
  24. Sambrook J. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press; 1989;
  25. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  26. Lonati S, Novembrino C, Ippolito S, et al. Analytical performance and method comparison study of the total homocysteine fluorescence polarization (FPIA) on the AxSYM analyzer. Clin Chem Lab Med. 2004;42:228–234
  27. Wilson DH, Yu J, Karian A, Kozlowski J, O’Reilly S. Development and multisite evaluation of an automated assay for B12 on the Abbott AxSYM analyzer. Clin Chem. 1999;45:428–429
  28. De Vecchi AF, Novembrino C, Patrosso MC, et al. Effect of incremental doses of folate on homocysteine and metabolically related vitamin concentrations in nondiabetic patients on peritoneal dialysis. ASAIO J. 2002;49:655–659
  29. Brady J, Wilson L, Mc Gregor L, Valente E, Orning L. Active B12: a rapid, automated assay for holotranscobalamin on the Abbott AxSYM analyzer. Clin Chem. 2008;54:567–573
  30. Trotti R, Carratelli M, Barbieri M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica. 2001;86:85–91
  31. Campise M, Bamonti F, Novembrino C, et al. Oxidative stress in kidney transplant patients. Transplantation. 2003;76:1474–1478
  32. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  33. Bamonti F, Moscato GA, Novembrino C, et al. Determination of serum Holotranscobalamin concentration by the AxSYM Active B12 assay (Abbott Diagnostics): cut-off point evaluation in clinical laboratory. Clin Chem Lab Med. 2010;48:249–253
  34. Clarke R, Sherliker P, Hin H, et al. Detection of vitamin B12 deficiency in older people by measuring vitamin B12 or the active fraction of vitamin B12, holotranscobalamin. Clin Chem. 2007;53:963–970
  35. Morkbak AL, Heimdal RM, Emmens K, et al. Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project. Clin Chem Lab Med. 2005;43:1058–1064
  36. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM. Low plasma levels of vitamin b6 are independently associated with a heightened risk of deep-vein thrombosis. Circulation. 2001;104:2442–2446
  37. Tawakol A, Omland T, Gerhard M, Wu JT, Creater MA. Hyperhomocyst(e)inemia is associated with impaired endothelium dependent vasodilation in humans. Circulation. 1997;95:1119–1121
  38. Lubos E, Loscalzo J, Handy DE. Homocysteine and glutathione peroxidase-1. Antioxid Redox Signal. 2007;9:1923–1940
  39. Papatheodorou L, Weiss N. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal. 2007;9:1941–1958
  40. Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids. 2003;25:409–417
  41. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med. 2008;233:109–122
  42. Ermens AA, Vlasveld LT, Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem. 2003;36:585–590
  43. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple form of insuline resistance. Nature. 2006;440:944–948
  44. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705–712
  45. Rytter E, Vessby B, Asgard R, et al. Glycaemic status in relation to oxidative stress and inflammation in well-controlled type 2 diabetes subjects. Br J Nutr. 2009;101:1423–1426
  46. Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle. 2005;4:1053–1056
  47. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, aGolam Mohi M. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like disease. Blood. 2010;115:3589–3597

PII: S0301-472X(10)00286-9

doi: 10.1016/j.exphem.2010.07.005

Experimental Hematology
Volume 38, Issue 11 , Pages 1058-1065 , November 2010

Article Tools